At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 25 enrolled
Drug / intervention
LY3819253 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Placebo-Controlled, Participant- and Investigator-Blind, Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of LY3819253 Administered Subcutaneously to Healthy Participants
In Brief
A Phase 1 clinical trial evaluating LY3819253 and Placebo for Healthy. Completed, enrolled 25 participants across 1 site.
Detailed Summary
The purpose of this study is to test the safety and tolerability of LY3819253 when it is given by injection just under the skin to healthy participants. Blood tests will be done to check how much LY3819253 is in the bloodstream and how long the body takes to eliminate it. Participation could last up to 16 weeks and may include up to six visits to the study center, with a one-week overnight stay.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
202120222023202420252026
Enrollment StartSep 2020
First PostedSep 2020
Primary CompletionDec 2020
TodayJul 2026
First PostedSep 3, 2020
Enrollment StartSep 2, 2020
Primary CompletionDec 28, 2020
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 5.8 years ago
Interventions
LY3819253drug
Administered SC.
Placebodrug
Administered SC.